<div id="readability-page-1"><h3>Claim 70% Off TipRanks Premium</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential</li></ul>BeOne Medicines Ltd ( (HK:6160) ) just unveiled an update. BeOne Medicines has reported the outcome of the latest offering period under its Fifth Amended and Restated 2018 Employee Share Purchase Plan, which allows eligible staff to buy shares, including ADSs, at a 15% discount funded through payroll deductions. At the close of the September 2, 2025 to February 27, 2026 window, 4,431 employees purchased 57,023 ADSs, equivalent to 741,299 shares or about 0.05% of issued capital, at a price set at 85% of the lower Nasdaq closing price at the start or end of the period. The company emphasized that participating employees are not directors, chief executives, substantial shareholders, or other capped categories under the Listing Rules, and that no performance targets or clawback provisions apply to these grants, which its compensation committee deems market competitive and consistent with past practice. The update underscores BeOne Medicines’ continued use of equity-based incentives to deepen employee ownership without material dilution, with 2,438,481 shares still available for future grants under the plan and no financial assistance provided by the company to fund purchases. The most recent analyst rating on (HK:6160) stock is a Hold with a HK$200.00 price target. To see the full list of analyst forecasts on BeOne Medicines Ltd stock, see the HK:6160 Stock Forecast page. More about BeOne Medicines Ltd BeOne Medicines Ltd is a Switzerland-incorporated company listed in Hong Kong that operates in the biopharmaceutical sector and offers its shares in the form of ordinary shares and American Depositary Shares. The company runs an Employee Share Purchase Plan to allow eligible staff across the group and designated subsidiaries to acquire equity at a discount, aligning employee interests with long-term shareholder value. Average Trading Volume: 3,585,821 Technical Sentiment Signal: Buy Current Market Cap: HK$286.6B For an in-depth examination of 6160 stock, go to TipRanks’ Overview page.</div>

513120

520880

159316

520690

513700

06160

BeOne Medicines Ltd has reported the results of its Fifth Amended and Restated 2018 Employee Share Purchase Plan, where 4,431 employees purchased 57,023 ADSs at a 15% discount. This represents about 0.05% of the company's issued capital. The plan aims to enhance employee ownership without significant dilution, with 2,438,481 shares available for future grants. The latest analyst rating for BeOne Medicines (HK:6160) is a Hold with a price target of HK$200.00. The company operates in the biopharmaceutical sector and is listed in Hong Kong.

BeOne Medicines Updates on Employee Share Purchase Plan Uptake